HIV

Some individuals produce antibodies that can recognize HIV.

When combining 2 complicated drug regimens, pharmacists have the opportunity to impact the lives of organ transplant patients and prevent adverse outcomes.

HIV can increase hospitalization for mental health issues compared with the general population.

Inhibiting immune cells’ oxygen-sensing capability prevented lung metastasis in mice.

Insight into the inner complexities of HIV and cytotoxic T lymphocyte evolution raise hopes for HIV cure.

Therapies that target certain gut bacteria may prevent complications and improve the efficiency of antiretroviral therapy.

Investigators at ViiV Healthcare are analyzing a 2-drug regimen of dolutegravir and lamivudine for HIV.

United Nations Program on HIV and AIDS seeks to reach 90% of HIV patients administered antiretroviral therapy to achieve durable viral suppression.

Research reveals potential drug targets for cervical cancer associated with human papillomavirus.

Bioethicist calls attention to urgent need for HIV treatment efforts in pregnant women worldwide.

Transmission rates reduced 96% among couples who both received treatment.

National Institutes of Health awards $9.4 million to improve HIV health care.

Researchers reveal how anti-HIV inhibitors bind to the wrong target.

Researchers seek to reduce the significant HIV risk among homeless people.

The combination of emtricitabine/tenofovir alafenamide did not show a treatment benefit over comparator therapies.

Early treatment for HIV and tuberculosis found to improve outcomes.

Findings point to need to target only non-damaged HIV in the body.

The transgender community includes a plethora of patients who can benefit from HIV/AIDS research. However, clinical trials rarely include transgender participants.

Patients administered PRO 140 monotherapy reach 2 years of complete remission in trial.

Study targets how HIV avoids immune system defenses.

Research evaluates how HIV evades immune system detection.

Researchers seek to develop drugs that block the Nef protein that is associated with HIV progressing to AIDS.

Patients taking mediations for both HIV and HCV must be closely monitored for drug-drug interactions.

Study will be the first to evaluate the role of metformin on liver fibrosis in HCV-HIV co-infected and HCV mono-infected patients.

Drug resistance not found to increase among patients with HIV.